Workflow
Youon(603776)
icon
Search documents
永安行(603776) - 中国国际金融股份有限公司关于永安行科技股份有限公司2025年度向特定对象发行A股股票之发行保荐书
2025-09-10 10:47
中国国际金融股份有限公司 关于 永安行科技股份有限公司 2025 年度向特定对象发行 A 股股票 之 发行保荐书 保荐机构 (北京市朝阳区建国门外大街 1 号国贸大厦 2 座 27 层及 28 层) 2025 年 9 月 永安行科技股份有限公司 发行保荐书 关于永安行科技股份有限公司 2025 年度向特定对象发行 A 股股票之发行保荐书 中国证券监督管理委员会、上海证券交易所: 永安行科技股份有限公司(以下简称"永安行"、"发行人"或"公司")拟申请 向特定对象发行71,819,411股的人民币普通股(A股)股票(以下简称"本次证券发行"、 "本次发行"或"向特定对象发行 A 股股票"),并已聘请中国国际金融股份有限公司 (以下简称"中金公司")作为本次证券发行的保荐机构(以下简称"保荐机构"或 "本机构")。 根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民共和国证 券法》(以下简称"《证券法》")、《证券发行上市保荐业务管理办法》(以下简称"《保 荐办法》")、《上市公司证券发行注册管理办法》(以下简称"《注册管理办法》")、《发 行证券的公司信息披露内容与格式准则第 27 号——发行保 ...
永安行(603776) - 容诚会计师事务所(特殊普通合伙)关于永安行科技股份有限公司向特定对象发行股票申请文件审核问询函中有关财务会计问题的专项说明
2025-09-10 10:47
| 2.关于前次募投项目及本次融资规模 | 2 | | --- | --- | | 3.关于业务及经营情况 | 14 | | 5.关于财务性投资 | 131 | 关于永安行科技股份有限公司 向特定对象发行证券申请文件 关于永安行科技股份有限公司 向特定对象发行股票申请文件审核问询函中有 关财务会计问题的专项说明 容诚专字[2025]210Z0170 号 容诚会计师事务所(特殊普通合伙) 中国·北京 E-mail:bj@rsmchina.com.cn https//WWW.rsm.global/china/ 2.关于前次募投项目及本次融资规模 根据申报材料及公开资料,1)公司 2020 年公开发行可转债拟投入共享助力车智 能系统的设计及投放项目 73,648万元,税后全部投资回收期为 4.25年(含建设期 2年), 税后投资内部收益率为 24.84%;截至 2025 年 4 月 30 日,投资进度为 64.18%。2)本 次募集资金不超过 8.4 亿元,拟全部用于补充流动资金。 请发行人说明:(1)公司前次募投项目进度较慢的具体原因,项目实施环境、可 行性是否发生较大变化,后续是否将继续实施该项目,尚未使用募集 ...
永安行(603776) - 永安行:2025年第三次临时股东会会议文件
2025-09-08 08:45
永安行科技股份有限公司 2025 年第三次临时股东会会议须知 为维护全体股东的合法利益,确保本次股东会能够依法行使职权,根据《中华人民共和国 公司法》《上市公司股东会规则》及本公司《章程》和《股东大会议事规则》的有关规定,特制 定本次股东会会议须知,望全体参会人员严格遵守并执行: 2 一、股东会召开过程中,参会股东或股东代理人(以下统称"股东")应当以维护全体股东 的合法权益、确保大会正常秩序和议事效率为原则,认真履行法定职责。 永安行科技股份有限公司 2025 年第三次临时股东会会议文件 目 录 永安行科技股份有限公司 2025 年第三次临时股东会 会议文件 | 2025 | 年第三次临时股东会会议须知 3 | | --- | --- | | 2025 | 年第三次临时股东会会议议程 4 | | | 议案一:关于变更注册资本、经营范围暨修订《公司章程》的议案 5 | 2025 年 9 月 16 日 永安行科技股份有限公司 2025 年第三次临时股东会会议文件 永安行科技股份有限公司 二、参会股东依法享有发言权、质询权、表决权等各项权利。股东应认真履行法定义务, 自觉遵守大会纪律,不得侵犯其他股东的权益,以确 ...
摩托车及其他板块9月5日涨2.61%,华洋赛车领涨,主力资金净流入1.24亿元
Market Performance - The motorcycle and other sectors increased by 2.61% on September 5, with Huafang Racing leading the gains [1] - The Shanghai Composite Index closed at 3812.51, up 1.24%, while the Shenzhen Component Index closed at 12590.56, up 3.89% [1] Stock Performance - Huafang Racing (834058) saw a significant rise of 29.98%, closing at 48.52 with a trading volume of 68,000 shares and a turnover of 327 million yuan [1] - Taotao Vehicle (301345) increased by 8.22%, closing at 199.50 with a trading volume of 26,200 shares and a turnover of 514 million yuan [1] - Other notable performers include Jiang Kui General (603766) up 5.05%, Yong'an Xing (603776) up 4.38%, and Lvtong Technology (301322) up 3.59% [1] Capital Flow - The motorcycle and other sectors experienced a net inflow of 124 million yuan from main funds, while retail funds saw a net outflow of 106 million yuan [1] - Specific stocks like Aima Technology (603529) had a main fund net inflow of 56.95 million yuan, while retail funds showed a net outflow of 27.17 million yuan [2] - Jiang Xin General (603766) also had a main fund net inflow of 27.81 million yuan, with retail funds experiencing a net outflow of 17.87 million yuan [2]
摩托车及其他板块9月3日跌0.9%,久祺股份领跌,主力资金净流入9596.44万元
Market Overview - On September 3, the motorcycle and other sectors fell by 0.9%, with Jiuyi Co. leading the decline [1] - The Shanghai Composite Index closed at 3813.56, down 1.16%, while the Shenzhen Component Index closed at 12472.0, down 0.65% [1] Stock Performance - Notable stock performances included: - Zhenghe Industrial: Closed at 46.80, up 1.83% with a trading volume of 31,600 shares and a turnover of 148 million yuan [1] - Taotao Vehicle: Closed at 187.20, up 1.07% with a trading volume of 15,800 shares [1] - Qianjiang Motorcycle: Closed at 16.89, up 0.84% with a trading volume of 154,700 shares and a turnover of 264 million yuan [1] - Jiuyi Co.: Closed at 69.83, up 0.47% with a trading volume of 185,800 shares and a turnover of 1.311 billion yuan [1] - Chuncheng Power: Closed at 262.50, down 0.89% with a trading volume of 11,000 shares [1] - Jiuyi Co. (Jiuyi Co. in another context): Closed at 18.92, down 6.57% with a trading volume of 121,700 shares and a turnover of 237 million yuan [2] Capital Flow - The motorcycle and other sectors saw a net inflow of 95.96 million yuan from main funds, while retail funds experienced a net outflow of 56.75 million yuan [2] - The capital flow for specific stocks included: - Jiuyi Co.: Main funds net inflow of 98.78 million yuan, retail funds net outflow of 51.21 million yuan [3] - Qianjiang Motorcycle: Main funds net inflow of 17.53 million yuan, retail funds net outflow of 32.57 million yuan [3] - Zhenghe Industrial: Main funds net inflow of 12.27 million yuan, retail funds net outflow of 10.68 million yuan [3]
摩托车及其他板块9月1日涨0.83%,永安行领涨,主力资金净流入1.13亿元
Market Overview - On September 1, the motorcycle and other sectors rose by 0.83% compared to the previous trading day, with Yong'an Xing leading the gains [1] - The Shanghai Composite Index closed at 3875.53, up 0.46%, while the Shenzhen Component Index closed at 12828.95, up 1.05% [1] Stock Performance - Yong'an Xing (603776) closed at 21.30, with a gain of 5.92% and a trading volume of 116,900 shares, amounting to a transaction value of 248 million yuan [1] - Other notable performers included Zhonglu Co. (600818) with a 2.65% increase, Qianli Technology (601777) up by 2.37%, and Chunfeng Power (603129) rising by 1.99% [1] Fund Flow Analysis - The motorcycle and other sectors saw a net inflow of 113 million yuan from institutional investors, while retail investors experienced a net outflow of 25.32 million yuan [2] - The main stocks with significant net inflows included Qianli Technology with 105 million yuan and Jiuyuan Company with 70.22 million yuan [3] Individual Stock Insights - Qianli Technology (601777) had a net inflow of 105 million yuan from institutional investors, but retail investors showed a net outflow of 61.90 million yuan [3] - Jiuyuan Company (689009) experienced a net inflow of 70.22 million yuan from institutional investors, while retail investors had a net outflow of 1.29 million yuan [3]
永安行2025年中报简析:净利润同比下降739.17%,公司应收账款体量较大
Zheng Quan Zhi Xing· 2025-08-28 22:59
Financial Performance - The company reported total revenue of 193 million yuan for the first half of 2025, a decrease of 21.29% year-on-year [1] - The net profit attributable to shareholders was -65.48 million yuan, representing a decline of 739.17% compared to the previous year [1] - In Q2 2025, total revenue was 110 million yuan, down 17.06% year-on-year, with a net profit of -40.85 million yuan, a decrease of 1452.46% [1] - The gross margin fell to 0.23%, a drop of 98.3% year-on-year, while the net margin was -33.16%, down 1067.29% [1] Financial Ratios and Metrics - The company's accounts receivable accounted for 86.55% of total revenue, indicating a significant reliance on credit [1] - Total expenses (selling, administrative, and financial) reached 38.72 million yuan, which is 20.05% of revenue, an increase of 26.29% year-on-year [1] - Earnings per share decreased to -0.27 yuan, a drop of 800.0% year-on-year, while operating cash flow per share was 0.14 yuan, down 47.34% [1] Historical Context - The company's historical median ROIC since its IPO is 20.03%, but the ROIC for the worst year, 2023, was -2.34%, indicating poor investment returns [3] - The company has reported losses in three out of seven annual reports since its listing, suggesting a fragile business model [3] - Despite recent poor performance, the company's cash assets are considered healthy, indicating some level of financial stability [3]
永安行科技股份有限公司2025年半年度报告摘要
Core Points - The company, Yong'an Technology Co., Ltd., is set to hold a half-year performance briefing on September 9, 2025, to discuss its operational results and financial status for the first half of 2025 [3][4][6] - The company has reported a total fundraising amount of RMB 886.48 million from the issuance of convertible bonds, with a net amount of RMB 870 million after deducting issuance costs [51][28] - The company plans to increase its registered capital from RMB 240.60 million to RMB 280.76 million due to the conversion of bonds into shares [47][48] Financial Data - As of June 30, 2025, the company has invested RMB 62.25 million of the raised funds into relevant projects [31] - The company has a total of RMB 57.36 million directly invested in fundraising projects as of December 31, 2024 [29] - The company has approved the use of up to RMB 4 billion of idle fundraising and RMB 6 billion of its own funds for cash management [50][52] Shareholder Meeting - The third extraordinary general meeting of shareholders for 2025 is scheduled for September 16, 2025, with both on-site and online voting options available [66][68] - The meeting will address various proposals that have already been reviewed and approved by the board of directors [69] Management and Governance - The board of directors and the supervisory board have confirmed the accuracy and completeness of the half-year report and related documents [1][18] - The company has established a three-party supervision agreement for the management of raised funds to ensure compliance with regulations [30]
永安行上半年净利-6547.56万元,同比大幅增亏
Bei Jing Shang Bao· 2025-08-28 05:17
Core Viewpoint - Yong'anxing (603776) reported a significant increase in losses for the first half of 2025, indicating financial challenges for the company [1] Financial Performance - In the first half of 2025, Yong'anxing achieved operating revenue of approximately 193 million yuan, a year-on-year decrease of 21.29% [1] - The net profit attributable to shareholders for the same period was approximately -65.48 million yuan, representing a substantial increase in losses compared to -7.80 million yuan in the same period last year [1]
永安行:8月27日召开董事会会议
Mei Ri Jing Ji Xin Wen· 2025-08-28 01:01
Group 1 - The company, Yong'anxing, announced on August 28 that its fifth board meeting was held on August 27, 2025, combining in-person and remote voting methods [1] - The meeting reviewed the proposal regarding the company's 2025 semi-annual report in full and summary [1] Group 2 - The news highlights a significant medical advancement with the world's first successful transplantation of gene-edited pig lungs into humans, raising questions about the timeline for clinical applications [1]